KR20120125576A - 소마토스타틴 유사체의 지속 방출을 위한 제약 조성물의 제조 방법 - Google Patents
소마토스타틴 유사체의 지속 방출을 위한 제약 조성물의 제조 방법 Download PDFInfo
- Publication number
- KR20120125576A KR20120125576A KR1020127021004A KR20127021004A KR20120125576A KR 20120125576 A KR20120125576 A KR 20120125576A KR 1020127021004 A KR1020127021004 A KR 1020127021004A KR 20127021004 A KR20127021004 A KR 20127021004A KR 20120125576 A KR20120125576 A KR 20120125576A
- Authority
- KR
- South Korea
- Prior art keywords
- hours
- composition
- lanreotide
- acetic acid
- over
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (16)
- 겔화성 소마토스타틴 유사체 염 및 산 수용액을 배합하는 단계;
생성된 혼합물을 1회만 동결건조시키는 단계; 및
동결건조물을 수화시키는 단계
를 포함하며, 조성물의 최종 pH가 pH 5 내지 7의 범위인, 주사가능한 지속 방출형 제약 조성물의 제조 방법. - 제1항에 있어서, 소마토스타틴 유사체가 란레오티드인 방법.
- 제1항에 있어서, 산이 아세트산인 방법.
- 제1항에 있어서, 조성물의 최종 pH가 5.8 내지 6.4의 범위인 방법.
- 제1항에 있어서, 산 수용액이, 필요한 최종 pH를 제공하기에 적합한 농도의 아세트산을 함유하는 것인 방법.
- 제1항에 있어서, 동결건조물의 수화에 사용된 산 수용액이 9.1 내지 10.5 중량%의 무수 아세테이트 함량을 제공하기에 적합한 농도의 아세트산을 함유하는 것인 방법.
- 제1항에 있어서, 25 ± 2 g/l의 란레오티드 및 15 ± 2 중량%의 아세트산을 제1 단계에서 배합하는 방법.
- 제1항에 있어서, 동결건조 단계 동안, 혼합물의 온도가
초기에는 실온에서 2℃ ± 1℃로 감소한 다음, 일정하게 유지되고;
2 ± 1℃에서 -40 ± 5℃로 추가로 감소한 다음, 일정하게 유지되고;
초기에는 -40 ± 5℃에서 25 ± 5℃로 증가한 다음, 일정하게 유지되고;
35 ± 5℃로 추가로 증가한 다음, 일정하게 유지되는 것인 방법. - 제7항에 있어서, 동결건조 단계의 지속시간이 40시간 이상, 보다 바람직하게는 60시간 이상인 방법.
- 제7항에 있어서, 동결건조 단계 동안, 혼합물의 온도가
초기에는 30분 이하, 바람직하게는 10분 이하에 걸쳐 감소한 다음, 3 ± 1시간 동안 일정하게 유지되고;
15분 이하, 바람직하게는 10분 이하에 걸쳐 추가로 감소한 다음, 3.5 ± 1시간 동안 일정하게 유지되고;
초기에는 20 ± 5시간에 걸쳐 증가한 다음, 40시간 이상 동안 일정하게 유지되고;
1 ± 0.5시간에 걸쳐 추가로 증가한 다음, 16시간 이상 동안 일정하게 유지되는 것인 방법. - 제7항에 있어서, 혼합물의 온도가 감소한 후, 대기압이 20 ± 5 μbar로 감소하고, 혼합물의 온도가 증가함에 따라 대기압이 일정하게 유지되는 것인 방법.
- 제1항 내지 제10항 중 어느 한 항에 있어서, 동결건조물이 용해되는 물의 양이 란레오티드 염을 완전히 용해시키는 데 필요한 양의 50% 미만, 바람직하게는 30% 미만, 보다 바람직하게는 10% 미만이며, 조성물에 반-고체 점조도를 부여하도록 조정되는 것인 방법.
- 제1항 내지 제11항 중 어느 한 항의 방법에 따라 제조된 지속 방출형 제약 조성물.
- 제12항에 있어서, 15일 이상, 바람직하게는 1개월, 보다 바람직하게는 2개월의 기간에 걸쳐 생체내에서 란레오티드를 방출할 수 있는 조성물.
- 제12항 또는 제13항에 있어서, 15 내지 35 중량%, 바람직하게는 25 ± 5 중량%, 보다 바람직하게는 대략 24.6 ± 2.5 중량%의 란레오티드 염기를 포함하는 조성물.
- 제12항 내지 제14항 중 어느 한 항에 있어서, 12개월 초과, 바람직하게는 24개월 초과 동안 2 내지 8℃에서 보관 후 사용하기에 적합한 조성물.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29464410P | 2010-01-13 | 2010-01-13 | |
US61/294,644 | 2010-01-13 | ||
PCT/EP2011/000069 WO2011085957A2 (en) | 2010-01-13 | 2011-01-11 | Process for the preparation of pharmaceutical compositions for the sustained release of somatostatin analogs |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20120125576A true KR20120125576A (ko) | 2012-11-15 |
KR101915820B1 KR101915820B1 (ko) | 2018-11-06 |
Family
ID=43743499
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020127021004A Active KR101915820B1 (ko) | 2010-01-13 | 2011-01-11 | 소마토스타틴 유사체의 지속 방출을 위한 제약 조성물의 제조 방법 |
Country Status (25)
Country | Link |
---|---|
US (3) | US9352012B2 (ko) |
EP (2) | EP3378468A1 (ko) |
JP (1) | JP6029472B2 (ko) |
KR (1) | KR101915820B1 (ko) |
CN (2) | CN105456206B (ko) |
AR (1) | AR079896A1 (ko) |
AU (1) | AU2011206728B2 (ko) |
BR (1) | BR112012017435A2 (ko) |
CA (1) | CA2786181C (ko) |
DK (1) | DK2523653T3 (ko) |
EA (1) | EA023128B1 (ko) |
ES (1) | ES2677012T3 (ko) |
HK (1) | HK1222807A1 (ko) |
HU (1) | HUE038200T2 (ko) |
IL (2) | IL220538A (ko) |
MX (1) | MX343112B (ko) |
NZ (1) | NZ600891A (ko) |
PL (1) | PL2523653T3 (ko) |
PT (1) | PT2523653T (ko) |
SG (1) | SG182548A1 (ko) |
TR (1) | TR201809874T4 (ko) |
TW (2) | TW201600108A (ko) |
UA (1) | UA108872C2 (ko) |
WO (1) | WO2011085957A2 (ko) |
ZA (1) | ZA201205160B (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160030232A (ko) * | 2013-07-09 | 2016-03-16 | 입센 파마 에스.에이.에스 | 란레오티드의 지속 방출을 위한 제약 조성물 |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011085957A2 (en) * | 2010-01-13 | 2011-07-21 | Ipsen Pharma S.A.S. | Process for the preparation of pharmaceutical compositions for the sustained release of somatostatin analogs |
TW201605488A (zh) | 2013-10-15 | 2016-02-16 | 大塚製藥股份有限公司 | 用以預防及/或治療多囊腎病之藥物 |
US10086049B2 (en) | 2013-10-22 | 2018-10-02 | Prolynx Llc | Conjugates of somatostatin analogues |
FR3079421B1 (fr) | 2018-03-28 | 2024-11-15 | Edix Sa | Presentations injectables, seringues et compositions a liberation prolongee et/ou controlee de lanreotide |
GR1009814B (el) * | 2019-07-29 | 2020-09-11 | Φαρματεν Α.Β.Ε.Ε. | Φαρμακευτικο σκευασμα που περιλαμβανει ενα πεπτιδιο αναλογο σωματοστατινης |
RU2742196C1 (ru) * | 2019-09-11 | 2021-02-03 | Общество с ограниченной ответственностью "Медицинские нанотехнологии" | Фармацевтическая композиция для приготовления инъекционного раствора при использовании в лечении магнитной гипертермии и способ ее получения |
CN112791177B (zh) * | 2019-10-28 | 2023-06-20 | 深圳翰宇药业股份有限公司 | 注射用生长抑素冻干组合物及其制备方法 |
LU101974B1 (en) | 2020-08-07 | 2022-02-07 | Pharmathen Sa | Process and apparatus for preparing viscous pharmaceutical formulations |
WO2022028739A1 (en) | 2020-08-07 | 2022-02-10 | Pharmathen S.A. | Process and apparatus for preparing viscous pharmaceutical formulations |
GR1010059B (el) * | 2020-08-10 | 2021-08-13 | Φαρματεν Α.Β.Ε.Ε. | Διαδικασια και συσκευη για την παρασκευη παχυρευστων φαρμακοτεχνικων μορφων |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1415378A (zh) * | 2002-10-22 | 2003-05-07 | 南京长澳医药科技有限公司 | 生长抑素冻干粉针及其制备工艺 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH085913B2 (ja) | 1985-09-12 | 1996-01-24 | ザ・アドミニストレ−タ−ズ・オブ・ザ・ツ−レイン・エデユケイシヨナル・フアンド | 治療用ソマトスタチン同族体 |
MD1591B2 (ro) | 1993-08-09 | 2001-01-31 | Biomeasure, Inc. | Derivaţi ai peptidelor cu activitate terapeutică |
US5595760A (en) | 1994-09-02 | 1997-01-21 | Delab | Sustained release of peptides from pharmaceutical compositions |
FR2762319A1 (fr) * | 1997-04-18 | 1998-10-23 | Pharma Biotech | Microcapsules presentant une liberation prolongee et leur procede de preparation |
FR2776520B1 (fr) | 1998-03-25 | 2000-05-05 | Sod Conseils Rech Applic | Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation |
US6506534B1 (en) * | 1999-09-02 | 2003-01-14 | Fujitsu Limited | Negative resist composition, method for the formation of resist patterns and process for the production of electronic devices |
IT1318539B1 (it) | 2000-05-26 | 2003-08-27 | Italfarmaco Spa | Composizioni farmaceutiche a rilascio prolungato per lasomministrazione parenterale di sostanze idrofile biologicamente |
US7098305B2 (en) | 2001-09-06 | 2006-08-29 | Ardana Bioscience Limited | Sustained release of microcrystalline peptide suspensions |
RS52966B (en) | 2002-09-27 | 2014-02-28 | Zentaris Gmbh | FORM OF THE THERAPEUTIC APPLICATION OF ACTIVE PEPTIDES WITH THE LONG TERM RELEASE OF THE ACTIVE INGREDIENT |
US6953447B2 (en) | 2002-10-22 | 2005-10-11 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S) | Pre-filled safety injection device with integrated waste collector |
GB0428151D0 (en) | 2004-12-22 | 2005-01-26 | Novartis Ag | Organic compounds |
US8158152B2 (en) * | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
GB0711656D0 (en) | 2007-06-15 | 2007-07-25 | Camurus Ab | Formulations |
EP2187901B1 (en) * | 2007-09-11 | 2012-08-08 | Mondobiotech Laboratories AG | Neuropeptide El optionally combined with ACTH (7-38) for use in anti-angiogenic therapy |
US20090181068A1 (en) | 2008-01-14 | 2009-07-16 | Dunn Richard L | Low Viscosity Liquid Polymeric Delivery System |
JP5951991B2 (ja) | 2008-08-12 | 2016-07-13 | ノバルティス アーゲー | 医薬組成物 |
EP2168983A1 (fr) | 2008-09-30 | 2010-03-31 | Ipsen Pharma | Nouveaux composés octapeptidiques et leur utilisation thérapeutique |
EP2376060B1 (en) | 2008-12-15 | 2012-09-19 | Novartis AG | Nanoparticle compositions |
WO2011085957A2 (en) * | 2010-01-13 | 2011-07-21 | Ipsen Pharma S.A.S. | Process for the preparation of pharmaceutical compositions for the sustained release of somatostatin analogs |
-
2011
- 2011-01-11 WO PCT/EP2011/000069 patent/WO2011085957A2/en active Application Filing
- 2011-01-11 EP EP18165921.0A patent/EP3378468A1/en not_active Withdrawn
- 2011-01-11 KR KR1020127021004A patent/KR101915820B1/ko active Active
- 2011-01-11 BR BR112012017435-5A patent/BR112012017435A2/pt not_active Application Discontinuation
- 2011-01-11 HU HUE11701938A patent/HUE038200T2/hu unknown
- 2011-01-11 PT PT117019380T patent/PT2523653T/pt unknown
- 2011-01-11 EA EA201290637A patent/EA023128B1/ru not_active IP Right Cessation
- 2011-01-11 CA CA2786181A patent/CA2786181C/en not_active Expired - Fee Related
- 2011-01-11 NZ NZ600891A patent/NZ600891A/en unknown
- 2011-01-11 US US13/522,297 patent/US9352012B2/en active Active
- 2011-01-11 TW TW104130927A patent/TW201600108A/zh unknown
- 2011-01-11 PL PL11701938T patent/PL2523653T3/pl unknown
- 2011-01-11 DK DK11701938.0T patent/DK2523653T3/en active
- 2011-01-11 ES ES11701938.0T patent/ES2677012T3/es active Active
- 2011-01-11 AU AU2011206728A patent/AU2011206728B2/en active Active
- 2011-01-11 TW TW100100923A patent/TWI536999B/zh active
- 2011-01-11 TR TR2018/09874T patent/TR201809874T4/tr unknown
- 2011-01-11 SG SG2012052403A patent/SG182548A1/en unknown
- 2011-01-11 CN CN201510888218.XA patent/CN105456206B/zh active Active
- 2011-01-11 CN CN201180005703.8A patent/CN102711728B/zh active Active
- 2011-01-11 MX MX2012007802A patent/MX343112B/es active IP Right Grant
- 2011-01-11 JP JP2012548370A patent/JP6029472B2/ja active Active
- 2011-01-11 EP EP11701938.0A patent/EP2523653B1/en active Active
- 2011-01-13 AR ARP110100112A patent/AR079896A1/es not_active Application Discontinuation
- 2011-11-01 UA UAA201209720A patent/UA108872C2/ru unknown
-
2012
- 2012-06-21 IL IL220538A patent/IL220538A/en active IP Right Grant
- 2012-07-11 ZA ZA2012/05160A patent/ZA201205160B/en unknown
-
2016
- 2016-04-27 US US15/139,533 patent/US10206968B2/en active Active
- 2016-09-21 HK HK16111087.3A patent/HK1222807A1/zh unknown
- 2016-10-26 IL IL248510A patent/IL248510A0/en unknown
-
2018
- 2018-12-26 US US16/232,207 patent/US20190167754A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1415378A (zh) * | 2002-10-22 | 2003-05-07 | 南京长澳医药科技有限公司 | 生长抑素冻干粉针及其制备工艺 |
Non-Patent Citations (1)
Title |
---|
중국특허공개공보 1415378(2003.05.07.) 1부. * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160030232A (ko) * | 2013-07-09 | 2016-03-16 | 입센 파마 에스.에이.에스 | 란레오티드의 지속 방출을 위한 제약 조성물 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101915820B1 (ko) | 소마토스타틴 유사체의 지속 방출을 위한 제약 조성물의 제조 방법 | |
Schwendeman et al. | Injectable controlled release depots for large molecules | |
CN104105479B (zh) | 鲁棒性控释制剂 | |
KR102769685B1 (ko) | 양극성 용매에서 안정한 치료 제형들의 제조방법 | |
JP6811270B2 (ja) | ランレオチドの持続放出用の医薬組成物 | |
KR20120015310A (ko) | 전립선암 치료용 조성물 | |
TW201249463A (en) | Pharmaceutical formulations | |
JP6374380B2 (ja) | ソマトスタチン受容体作動薬製剤 | |
US11590205B2 (en) | Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents | |
ES2716384T3 (es) | Composición farmacéutica de microesferas de liberación sostenida de goserelina | |
CN105342984A (zh) | 一种用于治疗急性胰腺炎的可注射温敏凝胶制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PA0105 | International application |
Patent event date: 20120810 Patent event code: PA01051R01D Comment text: International Patent Application |
|
PG1501 | Laying open of application | ||
A201 | Request for examination | ||
AMND | Amendment | ||
PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20160111 Comment text: Request for Examination of Application |
|
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20170601 Patent event code: PE09021S01D |
|
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20171213 Patent event code: PE09021S01D |
|
AMND | Amendment | ||
E601 | Decision to refuse application | ||
PE0601 | Decision on rejection of patent |
Patent event date: 20180621 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20171213 Comment text: Notification of reason for refusal Patent event code: PE06011S01I Patent event date: 20170601 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |
|
AMND | Amendment | ||
PX0901 | Re-examination |
Patent event code: PX09011S01I Patent event date: 20180621 Comment text: Decision to Refuse Application Patent event code: PX09012R01I Patent event date: 20180212 Comment text: Amendment to Specification, etc. Patent event code: PX09012R01I Patent event date: 20170801 Comment text: Amendment to Specification, etc. Patent event code: PX09012R01I Patent event date: 20160111 Comment text: Amendment to Specification, etc. |
|
PX0701 | Decision of registration after re-examination |
Patent event date: 20181016 Comment text: Decision to Grant Registration Patent event code: PX07013S01D Patent event date: 20180917 Comment text: Amendment to Specification, etc. Patent event code: PX07012R01I Patent event date: 20180621 Comment text: Decision to Refuse Application Patent event code: PX07011S01I Patent event date: 20180212 Comment text: Amendment to Specification, etc. Patent event code: PX07012R01I Patent event date: 20170801 Comment text: Amendment to Specification, etc. Patent event code: PX07012R01I Patent event date: 20160111 Comment text: Amendment to Specification, etc. Patent event code: PX07012R01I |
|
X701 | Decision to grant (after re-examination) | ||
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20181031 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20181031 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
PR1001 | Payment of annual fee |
Payment date: 20211005 Start annual number: 4 End annual number: 4 |
|
PR1001 | Payment of annual fee |
Payment date: 20220915 Start annual number: 5 End annual number: 5 |
|
PR1001 | Payment of annual fee |
Payment date: 20230918 Start annual number: 6 End annual number: 6 |
|
PR1001 | Payment of annual fee |
Payment date: 20240919 Start annual number: 7 End annual number: 7 |